Keywords
statins - coronavirus disease - COVID-19 - meta-analysis
The novel coronavirus disease 2019 (COVID-19) pandemic is sustained by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). This is the third coronavirus outbreak
that has occurred during the past 20 years, after those caused by SARS and Middle
East respiratory syndrome (MERS) coronaviruses (CoVs).[1]
[2] This new microorganism belongs to the CoV family, a class of enveloped, positive-sense,
single-stranded RNA viruses, which typically cause respiratory, enteric, hepatic,
and neurological diseases.[3]
[4]
SARS-CoV-2 is transmitted principally through respiratory droplets, though contact/fomites
and airborne (i.e., aerosol) transmission also plays a role in viral spread.[5] The virus penetrates into the host cells by primarily binding to angiotensin-converting
enzyme 2 (ACE2), and initially reproduces in the cells of lower and upper respiratory
tracts. Viral invasion might then be followed by a dysregulated host inflammatory
response in some genetically or clinically predisposed individuals, leading to life-threatening
episodes of acute respiratory distress syndrome (ARDS) and/or multiple organ failure.[6] ACE2 is a type I membrane protein expressed in lung, heart, kidney, and intestine
and is mainly associated with cardiovascular disease. The protein consists of an N-terminal
peptidase domain P and a C-terminal Collectrin-like domain that ends with a single
transmembrane helix and an approximately 40-residue intracellular segment.[7] In addition to cleavage of angiotensin (Ang) I to produce Ang-(1–9) and cleavage
of Ang II to produce Ang 1,7, ACE2 also provides a direct binding site for the spike
(S) proteins of CoVs. Early studies have shown that SARS-CoV-2 S protein binds to
human ACE2 with a 10- to 20-fold higher affinity than SARS-CoV, thus explaining its
higher virulence.[8]
The unfavorable progression of COVID-19, which can be seen in 5 to 15% of all patients
with SARS-CoV-2 infections, is characterized by a dysregulated inflammatory reaction,
which can also be accompanied by downregulation of ACE2 levels.[9]
[10] On one hand this event may contribute to reduce the likelihood of being infected,
on the other hand a lower ACE2 expression is associated with worse disease progression
in those who have already been infected by SARS-CoV-2, as will be more specifically
explained below.[9]
[10] The adverse effects of COVID-19 were initially thought to be primarily limited to
the respiratory tract (i.e., pneumonia and ARDS), but it is now clear that the virus
can extend systematically,[11] impacting a vast array of organs and tissues. The systemic propagation of the infection
is frequently associated with development of a prothrombotic state,[12] which manifests as micro- or macrovascular episodes of venous and/or arterial thrombosis,[13]
[14] associated with unfavorable prognosis.
Recent data show that SARS-CoV-2 could directly infect the vascular endothelium and
thereby impair endothelial cell function. Severe endothelial injuries associated with
the presence of intracellular viruses, disrupted cell membranes, thrombosis with microangiopathy,
and alveolar-capillary microthrombi have been described in COVID-19 patients.[15]
[16] In accordance with these findings, it is now clear that patients with vascular comorbidities
such as hypertension, cardiovascular disease, and even diabetes are at much greater
risk of poor outcome.[17]
[18]
[19]
Although no universal pharmacological treatment against SARS-CoV-2 has been established
to date, combinations of oxygenation, antiviral agents, immunosuppressive drugs, and
anticoagulants, along with other compounds, are individually used.[20]
[21] Among the various agents investigated, recent evidence has emerged that statins
(3-hydroxy-3-methylglutaryl coenzyme A –HMG-CoA– reductase inhibitors) may have a
beneficial effect in preventing disease progression.[22] Along with their lipid-lowering activity, statins are known to exert a kaleidoscope
of pleiotropic effects on inflammation and oxidative stress,[23] producing beneficial effects on cardiovascular disease and thrombosis.[24]
[25]
[26] Recent evidence has been provided that statins administration may be effective in
upregulating ACE2,[27] a mechanism that may lower the risk of developing severe ARDS in patients with SARS-CoV-2
infection,[28] since this enzyme promotes the enzymatic conversion of AngII into Ang 1,7, which
then counterbalances the proinflammatory and vasoconstrictive activity of the former
peptide.[29] Although the potential efficacy of antiatherosclerotic and antithrombotic mechanisms
attributed to statins in COVID-19 requires further investigation, these drugs may
represent a potentially promising therapy, at least as potential adjuvant drugs, especially
due to their low cost, widespread availability, and relatively modest side effects.[30]
[31]
Thus, statins have been suggested as part of the arsenal to treat and/or attenuate
COVID-19 symptoms and sequelae.[23] Therefore, this work is aimed to provide an overview of recent scientific literature
exploring the interplay between statins and outcome of COVID-19, especially in European
and North American populations.
Materials and Methods
We performed an electronic search in Medline (PubMed interface) and Scopus, using
the keywords “COVID-19” OR “SARS-CoV-2” AND “statin,” between 2019 and present time
(i.e., September 28, 2020), restricting the search to articles published in English.
The reference list of all documents was also reviewed to identify other potentially
eligible studies. The title, abstract, and full text of the articles identified according
to our search criteria were analyzed by two of the authors (D.O. and M.P.) and were
considered eligible for inclusion in this literature review if they were case series
(sample size >10) or observational studies reporting clear extractable data on the
use of statins in laboratory-confirmed COVID-19 patients, and compared data regarding
the use of statins between patients with severe/critical or nonsevere disease (or
ARDS, or pulmonary embolism diagnosed by computer tomography pulmonary angiography)
or between survivors and nonsurvivors. Severe/critical disease was defined as intensive
care unit admission, need for mechanical ventilation, or ARDS, pulmonary embolism
diagnosed by computer tomography pulmonary angiography, or death. We also excluded
studies that only reported the generic term “lipid-lowering agents” and no specific
information on the class of drug along with studies in patients with specific pathologies
that could lead to misinterpreting drug effect (i.e., patients with multiple myeloma).[32] Reviews, case reports, and other editorial materials with no original data were
also excluded. Disagreement arising during the selection assessment was resolved by
discussion and consensus.
The data extracted from each article included authors, year of publication, title
of the study, country, number of patients, age, number of patients taking statins
or not, percentage of patients under statins use who developed severe disease or death
versus those who did not, severity, infection criteria, and conclusions of the study
([Table 1]).
Table 1
Characteristics of the selected studies in patients hospitalized with COVID-19
Study
|
Setting
|
Study design
|
Sample size (COVID-19 positive)
|
Age (y)
|
Statins
Yes (n)
No (n)
|
|
% Patients on statin with severe disease or death
|
Endpoints
|
Conclusions
|
Wang et al (2020)[32]
|
United States
|
Retrospective
|
67
|
67 (median)
|
27
|
31
|
79% on statins vs. NA without
|
Mortality in patients with multiple myeloma
|
Statin use significantly associated with mortality in patients with multiple myeloma.
|
De Spiegeleer et al (2020)[35]
|
Belgium
|
Retrospective multicenter cohort study
|
154
|
79–93
|
31
|
123
|
19.4% on statins vs. 25.2% without
|
Severe disease or death
|
The effects of statin were positive but not statistically significant (OR: 0.75; CI:
0.24–1.87)
|
Mestre-Gómez et al. (2020)[36]
|
Spain
|
Retrospective single cohort study
|
91
|
56–73
|
27
|
64
|
22% on statins had PE vs. 35% without
|
PE confirmed at CT
|
No significant differences in treatment with statins in patients with and without
PE
|
Daniels et al (2020)[37]
|
CA, United States
|
Retrospective
|
170
|
40–78
|
46
|
124
|
43.4% on statins vs. 56.5% without
|
Admission in ICU or death
|
Statin use prior to admission was associated with reduced risk of severe COVID-19
|
Nguyen et al (2020)[38]
|
IL, United States
|
Retrospective
|
353
|
50–73
|
89
|
264
|
11.23% on statins vs. 13.2% without
|
Death
|
Statin use prior to admission was associated with reduced risk of mortality
|
Gupta et al (2020)[39]
|
NY, United States
|
Retrospective multicenter cohort study
|
1,296
|
60–81
|
648
|
648
|
17.2% on statins vs. 31% without
|
Death
|
Antecedent statin use in patients hospitalized with COVID-19 was associated with lower
inpatient mortality
|
Rodriguez-Nava et al (2020)[40]
|
IL, United States
|
Retrospective cohort Study
|
87
|
58–75
|
47 (on 39 survivors, unknown data for deceased patients)
|
40
|
NA 49% on statins vs. 62% without
|
Death
|
Slower progression to death associated with atorvastatin
|
McCarthy et al (2020)[41]
|
United States
|
Retrospective multicenter cohort study
|
247
|
50–76
|
187
|
60
|
48.0% on statins vs. 36.7% without
|
Admission in ICU or death
|
Use of statins is associated with unfavorable outcome.
|
Zhang et al (2020)[42]
|
Hubei, China
|
Retrospective
|
13,981
|
45–72
|
1,219
|
12,762
|
NA (reported as incidence rate: 0.21% on statins vs. 0.27 without)
|
Death during 28-day follow-up
|
Statin use was associated with a lower risk of all-cause mortality
|
Yan et al (2020)[43]
|
China
|
Retrospective multicenter
|
578
|
49 median age
|
15
|
563
|
33% on statins vs. 21% without
|
Severe disease
|
Despite low number of statin users, percentage of disease severity is higher in patients
with statins
|
Argenziano et al (2020)[44]
|
NY, United States
|
Case series
|
1,000
|
50–75
|
361
|
639
|
NA
|
Severe disease or death
|
NA
|
Dreher et al (2020)[45]
|
Germany
|
Retrospective
|
50
|
58–76
|
18 (lipid-lowering agents)
|
32
|
50.0% on statin vs. 46.8% no statin use
|
Evolution in ARDS
|
NA
|
Zeng et al (2020)[46]
|
China
|
Retrospective
|
1,031
|
46–74
|
38
|
993
|
3% on statin vs. NA no statin use
|
Death
|
NA
|
Grasselli et al (2020)[47]
|
Italy
|
Retrospective multicenter
|
3,988
|
55–69
|
479
|
3,509
|
NA
|
Death
|
NA
|
Abbreviations: ARDS, acute respiratory distress syndrome; CI, confidence interval;
CT, computed tomography; ICU, intensive care unit; NA, not available; OR, odds ratio;
PE, pulmonary embolism.
Studies were selected in accordance with PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-analyses) guidelines.[33]
For the purposes of pooling into a meta-analysis, Chinese studies (to limit ethnic
and sample heterogeneity) and studies that did not provide useful data for statistical
purposes were excluded from our analysis. A separate analysis of Chinese studies was
unfeasible, as they lacked the essential data for statistical pooling. A composite
endpoint of severe or fatal COVID-19 was employed for this analysis. The meta-analysis
was finally performed with calculation of pooled odds ratio (OR) and 95% confidence
interval (95% CI) using MetaXL, software Version 5.3 (EpiGear International Pty Ltd.,
Sunrise Beach, Australia). Heterogeneity among the included studies was probed employing
both the chi-square (χ2) test and the I
2 statistic. For the χ2 test, significant heterogeneity among the studies was designated with a Cochran's
Q p-value of <0.10. The I
2 statistic values were interpreted as 25, 50, and 75%, indicating low, moderate, and
high heterogeneity, respectively.[34] To evaluate potential sources for heterogeneity among the studies, subgroup analyses
by time of initiation of statin therapy (before or after hospital admission) and by
administration of azithromycin (a macrolide drug with significant drug interaction
with statins, especially fostering rhabdomyolysis) were performed.
Results
A total of 170 studies could be originally identified, 156 of which were finally excluded
because they were duplicates or did not fulfill the above-mentioned eligibility criteria
([Fig. 1]). Overall, 14 studies met the inclusion criteria,[32]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47] and are summarized in [Table 1]. After excluding studies from China or with inadequate data for pooling, the final
meta-analysis was limited to seven retrospective studies performed in Western countries,[35]
[36]
[37]
[38]
[39]
[40]
[41] totaling 2,398 patients, 1,075 of whom (44.8%) were taking statins ([Table 1]).
Fig. 1 PRISMA flow diagram of the literature search and selection process.
Three of the included studies were based on patients with similar age range (50–76
years old),[36]
[40]
[41] while the others included a mix of younger and older patients. Five out of seven
studies evaluated patients with statin treatment before hospital admission,[35]
[36]
[37]
[38]
[39] while the others considered treatments started before admission or during hospital
stay.[40]
[41] Notably, azithromycin[48] was also administered to the vast majority of patients included in the study by
McCarthy et al.[41] Two studies applied death as the endpoint, two reported disease severity as the
endpoint, and three reported both events.
The result of the meta-analysis of these seven studies performed in Western countries
are reported in [Fig. 2],[35]
[36]
[37]
[38]
[39]
[40]
[41] which demonstrate that COVID-19 patients taking statins had nearly 40% lower odds
of progressing to the composite endpoint of severe/critical illness or death (OR:
0.59; 95% CI: 0.35–0.99; Cochran's Q p = 0.02; I
2 = 60%). Individually, six of these seven studies reported a reduced OR (i.e., OR < 1;
protective effect of statins),[35]
[36]
[37]
[38]
[39]
[40] while in only one study was the OR >1 (i.e., OR: 1.60; 95% CI: 0.88–2.92).[41] After excluding McCartney's study, in which patients were also given azithromycin,
the beneficial effect of statins was magnified (OR: 0.52; 95% CI: 0.42–0.64; Cochran's
Q p = 0.73, I
2 = 0%). The results did not substantially change after excluding both studies in which
statin therapy was initiated after hospital admission (OR: 0.51; 95% CI: 0.41–0.64;
Cochran's Q p = 0.61, I
2 = 0%).[40]
[41] The funnel plot of all studies is shown in [Fig. 3], which demonstrated slight asymmetry.
Fig. 2 Forest plot of the meta-analysis.
Fig. 3 Funnel plot of the meta-analysis: statins' protective effect versus lack of protection
in hospitalized COVID-19 patients.
Discussion
This article aimed to review the current scientific literature which has explored
the potential impact of statins on clinical outcome of COVID-19 to date. Overall,
the results of our analysis suggest a beneficial effect of these cardiovascular drugs
in North American and European patients with SARS-CoV-2 infection.
In fatal cases of human SARS-CoV-2 (as well as of SARS-CoV-1 and MERS-CoV) infections,
patients mostly progress to a severe form of acute respiratory distress, which requires
mechanical ventilation and on autopsy demonstrates the classic histopathology findings
of ARDS.[49]
[50]
[51] ARDS is a life-threatening lung condition that causes diffuse alveolar damage in
the lung, with hyaline membrane formation in alveoli in the acute stage, and subsequent
interstitial widening, edema, and fibroblast proliferation in the organizing stage.[52]
[53]
Convincing evidence has been provided that release of inflammatory cytokines is strictly
associated with development and progression of ARDS, thus confirming that the onset
of a dysregulated inflammatory response is a primary event in promoting clinical deterioration
in COVID-19 patients.[54] The pathogenesis of COVID-19 encompasses hypercoagulability, inflammation, and decreased
endothelial integrity,[34] culminating in defective pulmonary vasoconstriction, shunting, and thrombotic microangiopathy.[55]
[56]
[57] A potential beneficial effect of statin use thus possibly entails modulation (i.e.,
inhibition) of many underlying pathways, leading to potentially powerful anti-inflammatory
and antithrombotic effects. In an animal model, atorvastatin was found to inhibit
the expression of toll-like receptors, a family of sensor proteins which activate
the myeloid differentiation primary response 88 pathway, thus underpinning its potential
favorable effect in patients with COVID-19.[58]
Despite numerous investigations, it remains uncertain if statins could have a role
in inhibiting the formation of thrombi in human subjects. To date, no study has demonstrated
a substantial impact of statins in prevention of thrombosis. As such, statins are
not clinically indicated for primary or secondary prevention of venous thromboembolism.[59]
[60] Thus, the beneficial effects of statins in COVID-19 are more likely to be attributed
to its anti-inflammatory properties (as well as improvement in endothelial function)
than to any significant antithrombotic direct effect.
Nonetheless, another potential beneficial mechanism of HMG-CoA reductase inhibitors
that needs to be mentioned in COVID-19 involves their effect on cholesterol reduction.
During viral infections, viruses require host lipid metabolism for survival since
lipids are implicated in membrane fusion, envelopment, and transformation.[61] The host plasma membrane contains microdomains rich in proteins, sphingolipids,
and cholesterol, named lipid rafts. An in vitro study investigated the role of these
molecular structure in modulating the interaction between the spike protein of SARS-CoV-1
with ACE2 receptor,[62] finding that cholesterol is required for efficient S-mediated binding to ACE2-containing
cells and its depletion decreased the infectivity by approximately 50% in a single
replication cycle. Given this evidence, it is possible that SARS-CoV-2 would benefit
from the presence of high cholesterol in the plasma membrane, which may hence facilitate
its penetration into host cells. Thus, a statin-mediated inhibition of cholesterol
biosynthesis pathway would result in decreased lipid raft formation and could hence
be seen as a putative protective mechanism against SARS-CoV-2, as well as against
other viral infections.[63]
[64]
Only one out of the seven studies included in our meta-analysis failed to report a
favorable effect of statins in patients with SARS-CoV-2 infection. However, the concomitant
administration of azithromycin in most patients enrolled in that study may have ultimately
biased the outcome. In fact, muscle injury, possibly emerging from combined administration
of the two drugs, may have contributed to attenuating the vascular benefits of statins,
as clearly highlighted.[41]
[65] As such, it is not surprising that the favorable outcome of statins in COVID-19
patients increased (i.e., from 40 to ~50% lower risk of unfavorable progression, with
narrower 95% CI) when this study was excluded from our meta-analysis. Unfortunately,
no specific analysis could be performed to assess whether any single statin formulation
would be more beneficial than another, since the type of drug administered was clearly
specified in only one study (i.e., Atorvastatin 40 mg).[39] Nonetheless, these findings support the start of new randomized controlled trials
investigating statins as adjunctive therapy in COVID-19.
Our meta-analysis has some limitations. First, this pooled analysis had a relatively
small sample size. Second, all studies were retrospective; two studies[39]
[40] included patients in whom statin therapy was only started upon hospital admission,
though their exclusion from the meta-analysis suggested an even larger favorable effect
of statins. Finally, the use of a composite outcome likely introduced some heterogeneity
into the analysis. However, subgroup analysis by study endpoint was unfeasible, as
individual studies did not report data required to segregate patients by outcome,
with the majority employing their own composite outcomes.
Conclusion
In conclusion, the results of this meta-analysis suggest a potential beneficial effect
of statins in patients with COVID-19, especially when these drugs were initiated before
hospital admission, but also lead the way to suggest that their administration could
be beneficial for all patients hospitalized with COVID-19, as additional treatment
for preventing unfavorable disease progression. Whether the favorable effect of statins
in patients with SARS-CoV-2 infection may be direct (e.g., lowering lipids and decreasing
the high cardiovascular risk characterizing COVID-19 patients),[66] or is more predictably mediated by the pleiotropic effects of these drugs (i.e.,
anti-inflammatory, anti-thrombotic, anti-hypertensive),[67] requires further investigation. Randomized controlled trials should be undertaken
to explore the potentially diversified effects of statins as adjuvant therapy for
improving outcomes in patients with SARS-CoV-2 infection. Irrespective of these considerations,
it seems reasonable to conclude that statin therapy should at minimum not be suspended
in patients with COVID-19.